These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 14508722)

  • 1. Current and ongoing trials with irinotecan in the United States.
    Fuchs CS
    Semin Oncol; 2003 Aug; 30(4 Suppl 12):9-17. PubMed ID: 14508722
    [No Abstract]   [Full Text] [Related]  

  • 2. [Capecitabine and irinotecan].
    Gasperoni S
    Suppl Tumori; 2004; 3(4):S107-8. PubMed ID: 15206231
    [No Abstract]   [Full Text] [Related]  

  • 3. The combination of capecitabine and oxaliplatin in metastatic colorectal cancer.
    Clin Colorectal Cancer; 2003 Feb; 2(4):205-9. PubMed ID: 12620138
    [No Abstract]   [Full Text] [Related]  

  • 4. Capecitabine in combination with irinotecan or oxaliplatin in advanced colorectal cancer.
    Clin Colorectal Cancer; 2003 Aug; 3(2):89-91. PubMed ID: 12952563
    [No Abstract]   [Full Text] [Related]  

  • 5. New studies highlight benefit of Xeloda in new combination treatments for colorectal cancer.
    Expert Rev Anticancer Ther; 2002 Jun; 2(3):241-2. PubMed ID: 12113038
    [No Abstract]   [Full Text] [Related]  

  • 6. [The new chemotherapy of colorectal cancers].
    Taïeb J; Boige V; Ducreux M
    Presse Med; 2002 Jan; 31(3):132-8. PubMed ID: 11859739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 25th European Society for Medical Oncology Congress. Hamburg, Germany. October 13-17, 2000.
    D'Orazio AI; Gambill BD
    Clin Colorectal Cancer; 2001 May; 1(1):10-5. PubMed ID: 12445373
    [No Abstract]   [Full Text] [Related]  

  • 8. Current status of capecitabine in the treatment of colorectal cancer.
    Rothenberg ML
    Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):16-22. PubMed ID: 12520635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers.
    Ducreux M; Köhne CH; Schwartz GK; Vanhoefer U
    Ann Oncol; 2003; 14 Suppl 2():ii17-23. PubMed ID: 12810453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Recent results of irinotecan therapy in colorectal cancer].
    Láng I; Hitre E
    Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Colorectal cancer: irinotecan in combination with newer drugs].
    Falcone A
    Tumori; 2001; 87(6):A31-3. PubMed ID: 11995705
    [No Abstract]   [Full Text] [Related]  

  • 12. Highlights from: 27th congress of the European Society for Medical Oncology. Nice, France. October 18-22, 2002.
    Maung K; Lee D; DeGrendele HC; Schilsky R; Chu E; Jain VK; Copur S
    Clin Colorectal Cancer; 2002 Nov; 2(3):140-5. PubMed ID: 12482329
    [No Abstract]   [Full Text] [Related]  

  • 13. Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil.
    Pfeiffer P; Sørbye H; Ehrsson H; Fokstuen T; Mortensen JP; Baltesgard L; Tveit KM; Øgreid D; Starkhammar H; Wallin I; Qvortrup C; Glimelius B
    Ann Oncol; 2006 Feb; 17(2):252-8. PubMed ID: 16291583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomised phase II study.
    Price TJ; Townsend AR; Khattak A
    Ann Oncol; 2010 Oct; 21(10):2121; author reply 2121-2. PubMed ID: 20860991
    [No Abstract]   [Full Text] [Related]  

  • 15. First-line therapeutic strategies in metastatic colorectal cancer.
    Davies JM; Goldberg RM
    Oncology (Williston Park); 2008 Nov; 22(13):1470-9. PubMed ID: 19133603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic therapy for colorectal cancer.
    Meyerhardt JA; Mayer RJ
    N Engl J Med; 2005 Feb; 352(5):476-87. PubMed ID: 15689586
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer.
    El-Rayes BF; Zalupski MM; Manza SG; Rusin B; Ferris AM; Vaishampayan U; Heilbrun LK; Venkatramanamoorthy R; Shields AF; Philip PA
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):283-9. PubMed ID: 17429629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capecitabine combinations in the treatment of advanced colorectal cancer.
    Fisher MD
    Clin Colorectal Cancer; 2001 Nov; 1(3):146-8. PubMed ID: 12450426
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study.
    Jackson NA; Barrueco J; Soufi-Mahjoubi R; Marshall J; Mitchell E; Zhang X; Meyerhardt J
    Cancer; 2009 Jun; 115(12):2617-29. PubMed ID: 19382200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer?
    Aguado C; García-Paredes B; Sotelo MJ; Sastre J; Díaz-Rubio E
    World J Gastroenterol; 2014 May; 20(20):6092-101. PubMed ID: 24876731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.